Results 1 to 10 of about 14,833,612 (178)

Dihydrotanshinone I exhibits antitumor effects via β-catenin downregulation in papillary thyroid cancer cell lines. [PDF]

Sci Rep
Thyroid cancer is the most common endocrine carcinoma and, among its different subtypes, the papillary subtype (PTC) is the most frequent. Generally, PTCs are well differentiated, but a minor percentage of PTCs are characterized by a worse prognosis and ...
Molteni E, Baldan F, Damante G, Allegri L.   +3 more
europepmc   +8 more sources

Dihydrotanshinone I enhanced BRAF mutant melanoma treatment efficacy by inhibiting the STAT3/SOX2 signaling pathway. [PDF]

Front Oncol
BackgroundThe Food and Drug Administration has approved the Serine/threonine-protein kinase B-raf (BRAF) inhibitor and Mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor combo as the first-line treatment for individuals with ...
Luo X, Duan Y, He J, Huang C, Liu J, Liu Y, Xu M, Dai Q, Yang Z.   +8 more
europepmc   +7 more sources

Regulation of HuR structure and function by dihydrotanshinone-I. [PDF]

Nucleic Acids Res, 2017
The Human antigen R protein (HuR) is an RNA-binding protein that recognizes U/AU-rich elements in diverse RNAs through two RNA-recognition motifs, RRM1 and RRM2, and post-transcriptionally regulates the fate of target RNAs.
Lal P, Cerofolini L, D'Agostino VG, Zucal C, Fuccio C, Bonomo I, Dassi E, Giuntini S, Di Maio D, Vishwakarma V, Preet R, Williams SN, Fairlamb MS, Munk R, Lehrmann E, Abdelmohsen K, Elezgarai SR, Luchinat C, Novellino E, Quattrone A, Biasini E, Manzoni L, Gorospe M, Dixon DA, Seneci P, Marinelli L, Fragai M, Provenzani A.   +27 more
europepmc   +12 more sources

Dihydrotanshinone I Targets PGAM1 to Induce SYVN1-Mediated Ubiquitination and Suppress Glycolysis in Hepatocellular Carcinoma. [PDF]

Phytother Res
Phosphoglycerate mutase 1 (PGAM1) is a glycolytic enzyme frequently overexpressed in hepatocellular carcinoma (HCC), contributing to tumor progression through aberrant glycolysis.
Xu R, Dai J, Gong R, Tu R, Wang Q, Zheng H, Zhou L, Wang S, Cai J, Sun H, Gao P, Gao P.   +11 more
europepmc   +3 more sources

Dihydrotanshinone I preconditions myocardium against ischemic injury via PKM2 glutathionylation sensitive to ROS. [PDF]

Acta Pharm Sin B, 2023
Ischemic preconditioning (IPC) is a potential intervention known to protect the heart against ischemia/reperfusion injury, but its role in the no-reflow phenomenon that follows reperfusion is unclear.
Wu X, Liu L, Zheng Q, Ye H, Yang H, Hao H, Li P.   +6 more
europepmc   +5 more sources

Free Cholesterol-Induced Liver Injury in Non-Alcoholic Fatty Liver Disease: Mechanisms and a Therapeutic Intervention Using Dihydrotanshinone I. [PDF]

Adv Sci (Weinh)
Build‐up of free cholesterol (FC) substantially contributes to the development and severity of non‐alcoholic fatty liver disease (NAFLD). Here, we investigate the specific mechanism by which FC induces liver injury in NAFLD and propose a novel ...
Shou JW, Ma J, Wang X, Li XX, Chen SC, Kang BH, Shaw PC.   +6 more
europepmc   +3 more sources

Effects of Dihydrotanshinone I on Proliferation and Invasiveness of Paclitaxel-Resistant Anaplastic Thyroid Cancer Cells. [PDF]

Int J Mol Sci, 2021
ATC is a very rare, but extremely aggressive form of thyroid malignancy, responsible for the highest mortality rate registered for thyroid cancer. In patients without known genetic aberrations, the current treatment is still represented by palliative ...
Allegri L, Capriglione F, Maggisano V, Damante G, Baldan F.   +4 more
europepmc   +7 more sources

Dihydrotanshinone I Inhibits the Lung Metastasis of Breast Cancer by Suppressing Neutrophil Extracellular Traps Formation. [PDF]

Int J Mol Sci, 2022
Breast cancer (BC) is a common female malignancy, worldwide. BC death is predominantly caused by lung metastasis. According to previous studies, Dihydrotanshinone I (DHT), a bioactive compound in Salvia miltiorrhiza Bunge (S.
Zhao H, Liang Y, Sun C, Zhai Y, Li X, Jiang M, Yang R, Li X, Shu Q, Kai G, Han B.   +10 more
europepmc   +4 more sources

Dihydrotanshinone I inhibits hepatocellular carcinoma cells proliferation through DNA damage and EGFR pathway.

PeerJ, 2023
Background The incidence and mortality of hepatocellular carcinoma (HCC) are globally on the rise. Dihydrotanshinone I, a natural product isolated from Salvia miltiorrhiza Bunge, has attracted extensive attention in recent years for its anti-tumour ...
Wang L, Xu X, Chen D, Li C.
europepmc   +5 more sources

Inhibitory Effects of Cryptotanshinone and Dihydrotanshinone I on Intracellular Trafficking of Viral Glycoproteins. [PDF]

J Microbiol Biotechnol
Antiviral agents that target the viral envelope surface glycoproteins can disrupt the interactions between the viral glycoproteins and host cell receptors, thereby preventing viral entry into host cells.
Muroi M, Lee DS.
europepmc   +4 more sources